Zimmer Biomet said net sales for Q1 2025 were $1.909 billion, up 1.1%, or 2.3% on a constant currency basis. Diluted earnings per share were $0.91, and adjusted diluted earnings per share were $1.81.

1. 01

   Zimmer Biomet said net sales for Q1 2025 were $1.909 billion, up 1.1%, or 2.3% on a constant currency basis. Diluted earnings per share were $0.91, and adjusted diluted earnings per share were $1.81.

2. 02

   The company reported adjusted operating profit of $500.5 million for Q1, with an adjusted operating margin of 26.2%. Adjusted operating profit was $539.4 million in the year-ago period, with an adjusted operating margin of 28.6%.

3. 03

   The company updated its full-year 2025 reported revenue change outlook to 5.7% to 8.2%, from the prior outlook of 1.0% to 3.5%. It said the adjusted diluted EPS outlook was updated to $7.90 to $8.10, from the prior outlook of $8.15 to $8.35.

4. 04

   The company reported operating cash flow of $382.8 million and free cash flow of $278.5 million for Q1 2025 (3 months). It also reported proceeds from senior notes of $1,748.1 million and redemption of senior notes of $863.0 million over the same period.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.